10/08/14 - 10:38 AM EDT
In an ongoing phase II study, ARC-520 dosed at 2 mg/kg induced a 0.3 log reduction in HBsAG, a measure of the presence of hepatitis B virus in the body.READ FULL POST
10/07/14 - 11:39 AM EDT
For the past three months, small-cap biotech stocks have been underperforming the broader market.READ FULL POST
09/30/14 - 05:53 PM EDT
Martin is super smart and will be a great asset somewhere, but he is not a CEO. I wish him the best.READ FULL POST
09/30/14 - 09:49 AM EDT
What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?READ FULL POST
09/29/14 - 12:17 PM EDT
Clovis Oncology shares are higher Monday because AstraZeneca, its direct competitor to develop a new, genetically targeted lung cancer drug, slipped this weekend.READ FULL POST
09/24/14 - 10:30 AM EDT
TAF is an improved version of Gilead's stalwart but patent challenged HIV drug Viread.READ FULL POST
09/24/14 - 08:14 AM EDT
Baxter has a hunger for cancer drugs with hair.READ FULL POST
09/22/14 - 07:48 PM EDT
Ebola patient Dr. Rick Sacra received treatment with Tekmira Pharmaceuticals' experimental ebola therapy TKM-Ebola for seven days, Nebraska Medical Center confirmed.READ FULL POST
09/22/14 - 08:59 AM EDT
The buyers of Northwest's debt want the stock price to decline before Feb. 15, 2015, because a lower stock price also will drop the conversion price of the notes.READ FULL POST
09/19/14 - 12:05 PM EDT
Activist investor Alex Denner is gaining an ally on Ariad's Board.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.